Design of an alternate antibody fragment format that can be produced in the cytoplasm of Escherichia coli.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 08 2023
30 08 2023
Historique:
received:
23
05
2023
accepted:
28
08
2023
medline:
1
9
2023
pubmed:
31
8
2023
entrez:
30
8
2023
Statut:
epublish
Résumé
With increased accessibility and tissue penetration, smaller antibody formats such as antibody fragments (Fab) and single chain variable fragments (scFv) show potential as effective and low-cost choices to full-length antibodies. These formats derived from the modular architecture of antibodies could prove to be game changers for certain therapeutic and diagnostic applications. Microbial hosts have shown tremendous promise as production hosts for antibody fragment formats. However, low target protein yields coupled with the complexity of protein folding result in production limitations. Here, we report an alternative antibody fragment format 'Fab
Identifiants
pubmed: 37648872
doi: 10.1038/s41598-023-41525-3
pii: 10.1038/s41598-023-41525-3
pmc: PMC10469194
doi:
Substances chimiques
Immunoglobulin G
0
Single-Chain Antibodies
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14188Informations de copyright
© 2023. Springer Nature Limited.
Références
Rettenbacher, L. A. et al. Microbial protein cell factories fight back?. Trends Biotechnol. 40, 576–590 (2022).
doi: 10.1016/j.tibtech.2021.10.003
Alibakhshi, A. et al. Targeted cancer therapy through antibody fragments-decorated nanomedicines. J. Control. Release 268, 323–334 (2017).
pubmed: 29107128
doi: 10.1016/j.jconrel.2017.10.036
Chen, H. et al. Strategies and applications of antigen-binding fragment (Fab) production in Escherichia coli. Pharm. Front. 03, e39–e49 (2021).
doi: 10.1055/s-0041-1735145
Kang, T. H. & Seong, B. L. Solubility, stability, and avidity of recombinant antibody fragments expressed in microorganisms. Front. Microbiol. 11, 1–10 (2020).
doi: 10.3389/fmicb.2020.01927
Nelson, A. L. Antibody fragments: Hope and hype. MAbs 2, 77–83 (2010).
pubmed: 20093855
pmcid: 2828581
doi: 10.4161/mabs.2.1.10786
Walsh, G. & Walsh, E. Biopharmaceutical benchmarks 2022. Nat. Biotechnol. 40, 1722–1760 (2022).
pubmed: 36471135
pmcid: 9735008
doi: 10.1038/s41587-022-01582-x
Sandomenico, A., Sivaccumar, J. P. & Ruvo, M. Evolution of Escherichia coli expression system in producing antibody recombinant fragments. Int. J. Mol. Sci. 21, 1–39 (2020).
doi: 10.3390/ijms21176324
Gani, K., Bhambure, R., Deulgaonkar, P., Mehta, D. & Kamble, M. Understanding unfolding and refolding of the antibody fragment (Fab). I. In-vitro study. Biochem. Eng. J. 164, 107764 (2020).
doi: 10.1016/j.bej.2020.107764
Lee, Y. K., Brewer, J. W., Hellman, R. & Hendershot, L. M. BiP and immunoglobulin light chain cooperate to control the folding of heavy chain and ensure the fidelity of immunoglobulin assembly. Mol. Biol. Cell 10, 2209–2219 (1999).
pubmed: 10397760
pmcid: 25436
doi: 10.1091/mbc.10.7.2209
Feige, M. J. et al. An unfolded CH1 domain controls the assembly and secretion of IgG antibodies. Mol. Cell 34, 569–579 (2009).
pubmed: 19524537
pmcid: 2908990
doi: 10.1016/j.molcel.2009.04.028
Humphreys, D. P. et al. A plasmid system for optimization of Fab′ production in Escherichia coli: Importance of balance of heavy chain and light chain synthesis. Protein Expr. Purif. 26, 309–320 (2002).
pubmed: 12406686
doi: 10.1016/S1046-5928(02)00543-0
Mehta, D., Chirmade, T., Tungekar, A. A., Gani, K. & Bhambure, R. Cloning and expression of antibody fragment (Fab) I: Effect of expression construct and induction strategies on light and heavy chain gene expression. Biochem. Eng. J. 176, 108189 (2021).
doi: 10.1016/j.bej.2021.108189
Ojima-Kato, T. et al. ‘Zipbody’ leucine zipper-fused Fab in E. coli in vitro and in vivo expression systems. Protein Eng. Des. Sel. 29, 149–157 (2016).
pubmed: 26902097
doi: 10.1093/protein/gzw001
Tungekar, A. A. & Ruddock, L. W. Efficient production of Fc fusion proteins in the cytoplasm of Escherichia coli: Dissecting and mitigating redox heterogeneity. Int. J. Mol. Sci. 23, 14740 (2022).
pubmed: 36499069
pmcid: 9737693
doi: 10.3390/ijms232314740
Thies, M. J. W. et al. Folding and oxidation of the antibody domain CH3. J. Mol. Biol. 319, 1267–1277 (2002).
pubmed: 12079363
doi: 10.1016/S0022-2836(02)00375-3
Gunasekaran, K. et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: Applications to bispecific molecules and monovalent IgG. J. Biol. Chem. 285, 19637–19646 (2010).
pubmed: 20400508
pmcid: 2885242
doi: 10.1074/jbc.M110.117382
Ridgway, J. B. B., Presta, L. G. & Carter, P. ‘Knobs-into-holes’ engineering of antibody C(H)3 domains for heavy chain heterodimerization. Protein Eng. 9, 617–621 (1996).
pubmed: 8844834
doi: 10.1093/protein/9.7.617
Moore, G. L. et al. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs 3, 546–557 (2011).
pubmed: 22123055
pmcid: 3242841
doi: 10.4161/mabs.3.6.18123
Davis, J. H. et al. SEEDbodies: Fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng. Des. Sel. 23, 195–202 (2010).
pubmed: 20299542
doi: 10.1093/protein/gzp094
Choi, H. J., Kim, Y. J., Lee, S. & Kim, Y. S. A heterodimeric fc-Based bispecific antibody simultaneously targeting vegfr-2 and met exhibits potent antitumor activity. Mol. Cancer Ther. 12, 2748–2759 (2013).
pubmed: 24132142
doi: 10.1158/1535-7163.MCT-13-0628
Wozniak-Knopp, G. et al. An antibody with fab-constant domains exchanged for a pair of CH3 domains. PLoS ONE 13, 1–19 (2018).
doi: 10.1371/journal.pone.0195442
Merchant, A. M. et al. An efficient route to human bispecific IgG. Nat. Biotechnol. 16, 677–681 (1998).
pubmed: 9661204
doi: 10.1038/nbt0798-677
Müller, A. et al. Nonnative disulfide bond formation activates the σ32-dependent heat shock response in Escherichia coli. J. Bacteriol. 195, 2807–2816 (2013).
pubmed: 23585533
pmcid: 3697257
doi: 10.1128/JB.00127-13
Dall’Acqua, W., Simon, A. L., Mulkerrin, M. G. & Carter, P. Contribution of domain interface residues to the stability of antibody C(H)3 domain homodimers. Biochemistry 37, 9266–9273 (1998).
pubmed: 9649307
doi: 10.1021/bi980270i
Matthews, B. W. Studies on protein stability with T4 lysozyme. Adv. Protein Chem. 46, 249–278 (1995).
pubmed: 7771320
doi: 10.1016/S0065-3233(08)60337-X
Gaciarz, A. et al. Systematic screening of soluble expression of antibody fragments in the cytoplasm of E. coli. Microb. Cell Fact. 15, 22 (2016).
pubmed: 26809624
pmcid: 4727284
doi: 10.1186/s12934-016-0419-5
Hatahet, F., Nguyen, V. D., Salo, K. E. H. & Ruddock, L. W. Disruption of reducing pathways is not essential for efficient disulfide bond formation in the cytoplasm of E. coli. Microb. Cell Fact. 9, 67 (2010).
pubmed: 20836848
pmcid: 2946281
doi: 10.1186/1475-2859-9-67
Nguyen, V. D. et al. Pre-expression of a sulfhydryl oxidase significantly increases the yields of eukaryotic disulfide bond containing proteins expressed in the cytoplasm of E. coli. Microb. Cell Fact. 10, 1 (2011).
pubmed: 21211066
pmcid: 3022669
doi: 10.1186/1475-2859-10-1
Bhatwa, A. et al. Challenges associated with the formation of recombinant protein inclusion bodies in escherichia coli and strategies to address them for industrial applications. Front. Bioeng. Biotechnol. 9, 1–18 (2021).
doi: 10.3389/fbioe.2021.630551
Chiu, M. L., Goulet, D. R., Teplyakov, A. & Gilliland, G. L. Antibody structure and function: The basis for engineering therapeutics. Antibodies 8, 55 (2019).
pubmed: 31816964
pmcid: 6963682
doi: 10.3390/antib8040055
Tetin, S. Y., Prendergast, F. G. & Venyaminov, S. Y. Accuracy of protein secondary structure determination from circular dichroism spectra based on immunoglobulin examples. Anal. Biochem. 321, 183–187 (2003).
pubmed: 14511682
doi: 10.1016/S0003-2697(03)00458-5
Tetin, S. Y. & Linthicum, D. S. Circular dichroism spectroscopy of monoclonal antibodies that bind a superpotent guanidinium sweetener ligand. Biochemistry 35, 1258–1264 (1996).
pubmed: 8573581
doi: 10.1021/bi951576h
Tetin, S. Y., Denzin, L. K., Weidner, K. M., Voss, E. W. & Mantulin, W. W. Comparative circular dichroism studies of an anti-fluorescein monoclonal antibody (Mab 4-4-20) and its derivatives1. Biochemistry 31, 12029–12034 (1992).
doi: 10.1021/bi00163a010
Akazawa-Ogawa, Y., Nagai, H. & Hagihara, Y. Heat denaturation of the antibody, a multi-domain protein. Biophys. Rev. 10, 255–258 (2018).
pubmed: 29256117
doi: 10.1007/s12551-017-0361-8
Atwell, S., Ridgway, J. B. B., Wells, J. A. & Carter, P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J. Mol. Biol. 270, 26–35 (1997).
pubmed: 9231898
doi: 10.1006/jmbi.1997.1116
Toughiri, R. et al. Comparing domain interactions within antibody Fabs with kappa and lambda light chains. MAbs 8, 1276–1285 (2016).
pubmed: 27454112
pmcid: 5058631
doi: 10.1080/19420862.2016.1214785
Lilie, H. Folding of the Fab fragment within the intact antibody. FEBS Lett. 417, 239–242 (1997).
pubmed: 9395304
doi: 10.1016/S0014-5793(97)01293-3
Gunasekaran, K., Wittekind, M., Yan, W. & Pentony, M. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects. WO/2009/089004 (Amgen Inc., 2009).
Gąciarz, A. & Ruddock, L. W. Complementarity determining regions and frameworks contribute to the disulfide bond independent folding of intrinsically stable scFv. PLoS ONE 12, 1–20 (2017).
doi: 10.1371/journal.pone.0189964
Tungekar, A. A. & Ruddock, L. W. Production of neutralizing antibody fragment variants in the cytoplasm of E. coli for rapid screening: SARS-CoV-2 a case study. Sci. Rep. 13, 4408 (2023).
pubmed: 36927743
pmcid: 10019796
doi: 10.1038/s41598-023-31369-2
Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369, 1010–1014 (2020).
pubmed: 32540901
pmcid: 7299284
doi: 10.1126/science.abd0827
Rathore, A. S. & Batra, J. Antibody production in microbial hosts. BioPharm Int. 29, 18–23 (2016).
Brinkmann, U. & Kontermann, R. E. The making of bispecific antibodies. MAbs 9, 182–212 (2017).
pubmed: 28071970
pmcid: 5297537
doi: 10.1080/19420862.2016.1268307
Ha, J. H., Kim, J. E. & Kim, Y. S. Immunoglobulin Fc heterodimer platform technology: From design to applications in therapeutic antibodies and proteins. Front. Immunol. 7, 1–16 (2016).
doi: 10.3389/fimmu.2016.00394
Kontermann, R. E. Dual targeting strategies with bispecific antibodies © 2012 Landes Bioscience. MAbs 4, 182–197 (2012).
pubmed: 22453100
pmcid: 3361654
doi: 10.4161/mabs.4.2.19000
Rader, C. Overview on concepts and applications of fab antibody fragments. Curr. Protoc. Protein Sci. 55, 1–14 (2009).
doi: 10.1002/0471140864.ps0609s55
Eleniste, P. P., Hofstetter, H. & Hofstetter, O. Expression and characterization of an enantioselective antigen-binding fragment directed against α-amino acids. Protein Expr. Purif. 91, 20–29 (2013).
pubmed: 23827208
doi: 10.1016/j.pep.2013.06.010
Demarest, S. J. et al. Engineering stability into Escherichia coli secreted Fabs leads to increased functional expression. Protein Eng. Des. Sel. 19, 325–336 (2006).
pubmed: 16672248
doi: 10.1093/protein/gzl016
Alt, M., Müller, R. & Kontermann, R. E. Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin γ1 Fc or CH3 region. FEBS Lett. 454, 90–94 (1999).
pubmed: 10413102
doi: 10.1016/S0014-5793(99)00782-6
Lu, D. et al. Di-diabody: A novel tetravalent bispecific antibody molecule by design. J. Immunol. Methods 279, 219–232 (2003).
pubmed: 12969563
doi: 10.1016/S0022-1759(03)00251-5
Hu, S. Z. et al. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 56, 3055–3061 (1996).
pubmed: 8674062
Von Kreudenstein, T. S. et al. Improving biophysical properties of a bispecific antibody scaffold to aid developability: Quality by molecular design. MAbs 5, 646–654 (2013).
doi: 10.4161/mabs.25632
Kang, H. J., Kim, H. J., Jung, M. S., Han, J. K. & Cha, S. H. Optimal expression of a Fab-effector fusion protein in Escherichia coli by removing the cysteine residues responsible for an interchain disulfide bond of a Fab molecule. Immunol. Lett. 184, 34–42 (2017).
pubmed: 28216260
doi: 10.1016/j.imlet.2017.02.008
Hölzer, W., Petersen, F., Strittmatter, W., Matzku, S. & Von Hoegen, I. A fusion protein of IL-8 and a Fab antibody fragment binds to IL-8 receptors and induces neutrophil activation. Cytokine 8, 214–221 (1996).
pubmed: 8833036
doi: 10.1006/cyto.1996.0030
Robinson, M. P. et al. Efficient expression of full-length antibodies in the cytoplasm of engineered bacteria. Nat. Commun. 6, 9072 (2015).
doi: 10.1038/ncomms9072
Jung, S. T. et al. Aglycosylated IgG variants expressed in bacteria that selectively bind FcγRI potentiate tumor cell killing by monocyte-dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 107, 604–609 (2010).
pubmed: 20080725
doi: 10.1073/pnas.0908590107
Li, Z., Kessler, W., Van Den Heuvel, J. & Rinas, U. Simple defined autoinduction medium for high-level recombinant protein production using T7-based Escherichia coli expression systems. Appl. Microbiol. Biotechnol. 91, 1203–1213 (2011).
pubmed: 21698378
doi: 10.1007/s00253-011-3407-z
Gasteiger, E. et al. ExPASy: The proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res. 31, 3784–3788 (2003).
pubmed: 12824418
pmcid: 168970
doi: 10.1093/nar/gkg563